Product Description
Mechanisms of Action: JAK1 Inhibitor,JAK2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vertex
Company Location: BOSTON MA 02210
Company CEO: Reshma Kewalramani
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Arthritis, Rheumatoid
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VX12-509-104 | P3 |
Completed |
Arthritis, Rheumatoid |
2014-07-01 |
|
| 2011-004419-22 | P2 |
Completed |
Arthritis, Rheumatoid |
2014-07-31 |
|
| 2012-004342-14 | P3 |
Terminated |
Arthritis, Rheumatoid |
2014-07-28 |
|
| VX11-509-102 | P2 |
Completed |
Arthritis, Rheumatoid |
2014-07-01 |
|
| 2012-003439-41 | P2 |
Completed |
Arthritis, Rheumatoid |
2014-04-25 |
|
| VX12-509-103 | P2 |
Completed |
Arthritis, Rheumatoid |
2014-01-01 |
|
| VX13-509-010 | P1 |
Completed |
Healthy Volunteers |
2013-08-01 |
|
| 2009-017438-32 | P2 |
Completed |
Arthritis, Rheumatoid |
2011-07-11 |
|
| VX09-509-101 | P2 |
Completed |
Arthritis, Rheumatoid |
2011-07-01 |
|
| VX08-509-002 | P1 |
Completed |
Healthy Volunteers |
None |